In advanced societies, laundry detergents are based on "linear" alkylbenzenesulfonates. Branched alkybenzenesulfonates (below right), used in former times, were abandoned because they biodegrade too slowly.

In 1973 it was proven for the first time that polyester degrades when disposed in bioactive material such as soil. Polyesters are water resistant and can be melted and shaped into sheets, bottles, and other products, making certain plastics now available as a biodegradable product. Following that discovery, polyhydroxylalkanoates (PHAs) were produced directly from renewable resources by microbes. They are approximately 95% cellular bacteria and can be manipulated by genetic strategies. The composition and biodegradability of PHAs can be regulated by blending them with other natural polymers. In the 1980s the company ICI Zenecca commercialized PHAs under the name Biopol. It was used for the production of shampoo bottles and other cosmetic products. Consumers were willing to pay more for this product because it was natural and biodegradable, a response which had not occurred before.

Now biodegradable technology has become a highly developed market with applications in product packaging, production and medicine. Biodegradable technology is concerned with the manufacturing science of biodegradable materials. It imposes science-based mechanisms of plant genetics into contemporary industral processes. Scientists and manufacturing corporations can help impact climate change by developing a use of plant genetics that would mimic some technologies. By looking to plants, such as biodegradable material harvested through photosynthesis, waste and toxins can be minimized.

Oxo-biodegradable technology, which has further developed biodegradable plastics, has also emerged. Oxo-biodegradation is defined by CEN (the European Standards Organisation) as "degradation resulting from oxidative and cell-mediated phenomena, either simultaneously or successively." Whilst sometimes described as "oxo-fragmentable," and "oxo-degradable" these terms describe only the first or oxidative phase and should not be used for material which degrades by the process of oxo-biodegradation defined by CEN: the correct description is "oxo-biodegradable."

By combining plastic products with very large polymer molecules, which contain only carbon and hydrogen, with oxygen in the air, the product is rendered capable of decomposing in anywhere from a week to one to two years. This reaction occurs even without prodegradant additives but at a very slow rate. That is why conventional plastics, when discarded, persist for a long time in the environment. Oxo-biodegradable formulations catalyze and accelerate the biodegradation process but it takes considerable skill and experience to balance the ingredients within the formulations so as to provide the product with a useful life for a set period, followed by degradation and biodegradation.

Biodegradable technology is especially utilized by the bio-medical community. Biodegradable polymers are classified into three groups:

medical, ecological, and dual application, while in terms of origin they are divided into two groups: natural and synthetic. The Clean Technology Group is exploiting the use of supercritical carbon dioxide, which under high pressure at room temperature is a solvent that can use biodegradable plastics to make polymer drug coatings. The polymer (meaning a material composed of molecules with repeating structural units that form a long chain) is used to encapsulate a drug prior to injection in the body and is based on lactic acid, a compound normally produced in the body, and is thus able to be excreted naturally. The coating is designed for controlled release over a period of time, reducing the number of injections required and maximizing the therapeutic benefit. Professor Steve Howdle states that biodegradable polymers are particularly attractive for use in drug delivery, as once introduced into the body they require no retrieval or further manipulation and are degraded into soluble, non-toxic by-products. Different polymers degrade at different rates within the body and therefore polymer selection can be tailored to achieve desired release rates.

Other biomedical applications include the use of biodegradable, elastic shape-memory polymers. Biodegradable implant materials can now be used for minimally invasive surgical procedures through degradable thermoplastic polymers. These polymers are now able to change their shape with increase of temperature, causing shape memory capabilities as well as easily degradable sutures. As a result, implants can now fit through small incisions, doctors can easily perform complex deformations, and sutures and other material aides can naturally biodegrade after a completed surgery.

Decomposition is the process by which organic substances are broken down into simpler matter. The process is a part of nutrient cycle and is essential for recycling the finite matter that occupies physical space in the biosphere. Bodies of living organisms begin to decompose shortly after death. Animals, such as worms, also help decompose the organic materials. Organisms that do this are known as decomposers. Although no two organisms decompose in the same way, they all undergo the same sequential stages of decomposition. The science which studies decomposition is generally referred to as "taphonomy" from the Greek word "taphos", meaning tomb.

One can differentiate abiotic from biotic decomposition (biodegradation). The former means "degradation of a substance by chemical or physical processes, e.g., hydrolysis. The latter means "the metabolic breakdown of materials into simpler components by living organisms", typically by microorganisms.

As many of the clinical signs and symptoms of ethylene glycol poisoning are nonspecific and occur in many poisonings the diagnosis is often difficult. It is most reliably diagnosed by the measurement of the blood ethylene glycol concentration. Ethylene glycol in biological fluids can be determined by gas chromatography. Many hospital laboratories do not have the ability to perform this blood test and in the absence of this test the diagnosis must be made based on the clinical presentation of the patient. In this situation a helpful test to diagnose poisoning is the measurement of the osmolal gap. The patients' serum osmolality is measured by freezing point depression and then compared with the predicted osmolality based on the patients' measured sodium, glucose, blood urea nitrogen, and any ethanol that may have been ingested. The presence of a large osmolal gap supports a diagnosis of ethylene glycol poisoning. However, a normal osmolar gap does not rule out ethylene glycol exposure because of wide individual variability.

The increased osmolal gap is caused by the ethylene glycol itself. As the metabolism of ethylene glycol progresses there will be less ethylene glycol and this will decrease the blood ethylene glycol concentration and the osmolal gap making this test less useful. Additionally, the presence of other alcohols such as ethanol, isopropanol, or methanol or conditions such as alcoholic or diabetic ketoacidosis, lactic acidosis, or kidney failure may also produce an elevated osmolal gap leading to a false diagnosis.

Other laboratory abnormalities may suggest poisoning, especially the presence of a metabolic acidosis, particularly if it is characterized by a large anion gap. Large anion gap acidosis is usually present during the initial stage of poisoning. However, acidosis has a large number of differential diagnosis, including poisoning from methanol, salicylates, iron, isoniazid, paracetamol, theophylline, or from conditions such as uremia or diabetic and alcoholic ketoacidosis. The diagnosis of ethylene glycol poisoning should be considered in any patient with a severe acidosis. Urine microscopy can reveal needle or envelope-shaped calcium oxalate crystals in the urine which can suggest poisoning; although these crystals may not be present until the late stages of poisoning. Finally, many commercial radiator antifreeze products have fluorescein added to enable radiator leaks to be detected using a Wood's lamp. Following ingestion of antifreeze products containing ethylene glycol and fluorescein, a Wood's lamp may reveal fluorescence of a patient’s mouth area, clothing, vomitus, or urine which can help to diagnose poisoning.

A body buried in a sufficiently dry environment may be well preserved for decades. This was observed in the case for murdered civil rights activist Medgar Evers, who was found to be almost perfectly preserved over 30 years after his death, permitting an accurate autopsy when the case of his murder was re-opened in the 1990s.

Bodies submerged in a peat bog may become naturally "embalmed", arresting decomposition and resulting in a preserved specimen known as a bog body. The time for an embalmed body to be reduced to a skeleton varies greatly. Even when a body is decomposed, embalming treatment can still be achieved (the arterial system decays more slowly) but would not restore a natural appearance without extensive reconstruction and cosmetic work, and is largely used to control the foul odors due to decomposition.

An animal can be preserved almost perfectly, for millions of years in a resin such as amber.

There are some examples where bodies have been inexplicably preserved (with no human intervention) for decades or centuries and appear almost the same as when they died. In some religious groups, this is known as incorruptibility. It is not known whether or for how long a body can stay free of decay without artificial preservation.

Treatment for antifreeze poisoning needs to be started as soon after ingestion as possible to be effective; the earlier treatment is started, the greater the chance of survival. Cats must be treated within 3 hours of ingesting of antifreeze to be effective, while dogs must be treated within 8–12 hours of ingestion. Once kidney failure develops, the prognosis is poor.

Generally, if the patient is treated and survives then a full recovery is expected. Patients who present early to medical facilities and have prompt medical treatment typically will have a favorable outcome. Alternatively, patients presenting late with signs and symptoms of coma, hyperkalemia, seizures, or severe acidosis have a poor prognosis. Patients who develop severe central nervous system manifestations or stroke who survive may have long term neurologic dysfunction; in some cases they may recover, although convalescence may be prolonged. The most significant long-term complication is related to the kidneys. Cases of permanent kidney damage, often requiring chronic dialysis or kidney transplantation, have been reported after severe poisoning.

Three main approaches have been used to prevent or reduce the incidence of Tay–Sachs:

- Prenatal diagnosis. If both parents are identified as carriers, prenatal genetic testing can determine whether the fetus has inherited a defective gene copy from both parents. Chorionic villus sampling (CVS), the most common form of prenatal diagnosis, can be performed between 10 and 14 weeks of gestation. Amniocentesis is usually performed at 15–18 weeks. These procedures have risks of miscarriage of 1% or less.

- Preimplantation genetic diagnosis. By retrieving the mother's eggs for in vitro fertilization, it is possible to test the embryo for the disorder prior to implantation. Healthy embryos are then selected and transferred into the mother's womb, while unhealthy embryos are discarded. In addition to Tay–Sachs disease, preimplantation genetic diagnosis has been used to prevent cystic fibrosis and sickle cell anemia among other genetic disorders.

- Mate selection. In Orthodox Jewish circles, the organization Dor Yeshorim carries out an anonymous screening program so that carrier couples for Tay–Sachs and other genetic disorders can avoid marriage.

As of 2010, even with the best care, children with infantile Tay–Sachs disease usually die by the age of 4.

Tay–Sachs disease is a rare autosomal recessive genetic disorder that causes a progressive deterioration of nerve cells and of mental and physical abilities that begins around six months of age and usually results in death by the age of four. It is the most common of the GM2 gangliosidoses. The disease occurs when harmful quantities of cell membrane gangliosides accumulate in the brain's nerve cells, eventually leading to the premature death of the cells.

The GM2 gangliosidoses are a group of three related genetic disorders that result from a deficiency of the enzyme beta-hexosaminidase. This enzyme catalyzes the biodegradation of fatty acid derivatives known as gangliosides. The diseases are better known by their individual names.

Beta-hexosaminidase is a vital hydrolytic enzyme, found in the lysosomes, that breaks down lipids. When beta-hexosaminidase is no longer functioning properly, the lipids accumulate in the nervous tissue of the brain and cause problems. Gangliosides are made and biodegraded rapidly in early life as the brain develops. Except in some rare, late-onset forms, the GM2 gangliosidoses are fatal.

All three disorders are rare in the general population. Tay-Sachs disease has become famous as a public health model because an enzyme assay test for TSD was discovered and developed in the late 1960s and early 1970s, providing one of the first "mass screening" tools in medical genetics. It became a research and public health model for understanding and preventing all autosomal genetic disorders.

Tay-Sachs disease, AB variant, and Sandhoff disease might easily have been defined together as a single disease, because the three disorders are associated with failure of the same metabolic pathway and have the same outcome. Classification and naming for many genetic disorders reflects history, because most diseases were first observed and classified based on biochemistry and pathophysiology before genetic diagnosis was available. However, the three GM2 gangliosidoses were discovered and named separately. Each represents a distinct molecular point of failure in a subunit that is required for activation of the enzyme.